Skip to main content

Advertisement

Log in

Management of patients with the immune reconstitution inflammatory syndrome

  • Published:
Current HIV/AIDS Reports Aims and scope Submit manuscript

Abstract

A significant proportion of patients present with the immune reconstitution inflammatory syndrome (IRIS) after commencing antiretroviral therapy (ART). This syndrome is most frequently associated with infective causes. The lack of evidence-based treatment guidelines poses challenges in the management of these patients. Alternative causes for deterioration should be excluded, and optimization of treatment for the underlying opportunistic infection is essential. In addition, anti-inflammatory or immunomodulatory therapy may be considered, particularly in severe cases. Corticosteroids, the only treatment for which clinical trial data exist (for treating paradoxical tuberculosis-associated IRIS), are the treatment most frequently used in IRIS. Limited anecdotal reports of benefit exist for other agents, including NSAIDs, pentoxifylline, montelukast, thalidomide, and hydroxychloroquine. Therapeutic procedures (eg, aspiration of pus collections) play an important role in some patients. Interruption of ART may be considered in life-threatening forms of IRIS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. French MA: HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis 2009, 48:101–107.

    Article  PubMed  Google Scholar 

  2. Riddell JT, Kaul DR, Karakousis PC, et al.: Mycobacterium avium complex immune reconstitution inflammatory syndrome: long term outcomes. J Transl Med 2007, 5:50.

    Article  PubMed  Google Scholar 

  3. Burman W, Weis S, Vernon A, et al.: Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis. Int J Tuberc Lung Dis 2007, 11:1282–1289.

    PubMed  CAS  Google Scholar 

  4. Meintjes G, Rangaka MX, Maartens G, et al.: Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clin Infect Dis 2009, 48:667–676.

    Article  PubMed  Google Scholar 

  5. Bicanic T, Harrison T, Niepieklo A, et al.: Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis 2006, 43:1069–1073.

    Article  PubMed  CAS  Google Scholar 

  6. Drake A, Mijch A, Sasadeusz J: Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART. Clin Infect Dis 2004, 39:129–132.

    Article  PubMed  Google Scholar 

  7. Baker JV, Boulware DR, Bohjanen PR: A case for treating high hepatitis B DNA levels before starting HIV therapy. AIDS 2006, 20:2402–2403.

    Article  PubMed  Google Scholar 

  8. Hardwick C, White D, Morris E, et al.: Montelukast in the treatment of HIV associated immune reconstitution disease. Sex Transm Infect 2006, 82:513–514.

    Article  PubMed  CAS  Google Scholar 

  9. Lesho E: Evidence base for using corticosteroids to treat HIV-associated immune reconstitution syndrome. Expert Rev Anti Infect Ther 2006, 4:469–478.

    Article  PubMed  CAS  Google Scholar 

  10. McGee S, Hirschmann J: Use of corticosteroids in treating infectious diseases. Arch Intern Med 2008, 168:1034–1046.

    Article  PubMed  CAS  Google Scholar 

  11. Lawn SD, Bekker LG, Miller RF: Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005, 5:361–373.

    Article  PubMed  Google Scholar 

  12. Meintjes G, Wilkinson RJ, Morroni C, et al.: Randomized placebo-controlled trial of prednisone for the TB immune reconstitution inflammatory syndrome [abstract 34]. Presented at the 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada; February 8–11, 2009.

  13. Pepper DJ, Marais S, Maartens G, et al.: Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. Clin Infect Dis 2009, 48:e96–e107.

    Article  PubMed  Google Scholar 

  14. Tan K, Roda R, Ostrow L, et al.: PML-IRIS in patients with HIV infection. Clinical manifestations and treatment with steroids. Neurology 2009, 72:1458–1464.

    Article  PubMed  CAS  Google Scholar 

  15. Rajeswaran G, Becker JL, Michailidis C, et al.: The radiology of IRIS (immune reconstitution inflammatory syndrome) in patients with mycobacterial tuberculosis and HIV co-infection: appearances in 11 patients. Clin Radiol 2006, 61:833–843.

    Article  PubMed  CAS  Google Scholar 

  16. Tuon FF, Mulatti GC, Pinto WP, et al.: Immune reconstitution inflammatory syndrome associated with disseminated mycobacterial infection in patients with AIDS. AIDS Patient Care STDS 2007, 21:527–532.

    Article  PubMed  Google Scholar 

  17. Dautremer J, Pacanowski J, Girard PM, et al.: A new presentation of immune reconstitution inflammatory syndrome followed by a severe paradoxical reaction in an HIV-1-infected patient with tuberculous meningitis. AIDS 2007, 21:381–382.

    Article  PubMed  Google Scholar 

  18. Lortholary O, Fontanet A, Memain N, et al.: Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 2005, 19:1043–1049.

    Article  PubMed  Google Scholar 

  19. Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, et al.: Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 2002, 81:213–227.

    Article  Google Scholar 

  20. Clark BM, Krueger RG, Price P, French MA: Compartmentalization of the immune response in varicella zoster virus immune restoration disease causing transverse myelitis. AIDS 2004, 18:1218–1221.

    Article  PubMed  Google Scholar 

  21. Sumner CJ, Newman M, Jay CA: Recurrent myelopathy after HAART in a patient with spinal mycobacterial infection. Neurology 2003, 61:139–140.

    PubMed  Google Scholar 

  22. Gray F, Bazille C, Adle-Biassette H, et al.: Central nervous system immune reconstitution disease in acquired immunodeficiency syndrome patients receiving highly active antiretroviral treatment. J Neurovirol 2005, 11(Suppl 3):16–22.

    Article  PubMed  Google Scholar 

  23. Du Pasquier RA, Kuroda MJ, Zheng Y, et al.: A prospective study demonstrates an association between JC virusspecific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 2004, 127:1970–1978.

    Article  PubMed  Google Scholar 

  24. Du Pasquier RA, Koralnik IJ: Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial? J Neurovirol 2003, 9(Suppl 1):25–31.

    Article  PubMed  Google Scholar 

  25. Silva MT, Pacheco MC Jr, Vaz B: Inflammatory progressive multifocal leukoencephalopathy after antiretroviral treatment. AIDS 2006, 20:469–471.

    Article  PubMed  Google Scholar 

  26. Berger JR: Steroids for PML-IRIS. A double-edged sword? Neurology 2009, 72:1454–1455.

    Article  PubMed  Google Scholar 

  27. Henderson HW, Mitchell SM: Treatment of immune recovery vitritis with local steroids. Br J Ophthalmol 1999, 83:540–545.

    Article  PubMed  CAS  Google Scholar 

  28. Karavellas MP, Lowder CY, Macdonald C, et al.: Immune recovery vitritis associated with inactive cytomegalovirus retinitis: a new syndrome. Arch Ophthalmol 1998, 116:169–175.

    PubMed  CAS  Google Scholar 

  29. Manabe YC, Campbell JD, Sydnor E, Moore RD: Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J Acquir Immune Defic Syndr 2007, 46:456–462.

    Article  PubMed  CAS  Google Scholar 

  30. McComsey GA, Whalen CC, Mawhorter SD, et al.: Placebo-controlled trial of prednisone in advanced HIV-1 infection. AIDS 2001, 15:321–327.

    Article  PubMed  CAS  Google Scholar 

  31. Elliott AM, Luzze H, Quigley MA, et al.: A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis. J Infect Dis 2004, 190:869–878.

    Article  PubMed  CAS  Google Scholar 

  32. Venkataramana A, Pardo CA, McArthur JC, et al.: Immune reconstitution inflammatory syndrome in the CNS of HIVinfected patients. Neurology 2006, 67:383–388.

    Article  PubMed  CAS  Google Scholar 

  33. Volkow PF, Cornejo P, Zinser JW, et al.: Life-threatening exacerbation of Kaposi’s sarcoma after prednisone treatment for immune reconstitution inflammatory syndrome. AIDS 2008, 22:663–665.

    Article  PubMed  Google Scholar 

  34. Dalessandro L, Bottaro E: Reactivation of CMV retinitis after treatment with subtenon corticosteroids for immune recovery uveitis in a patient with AIDS. Scand J Infect Dis 2002, 34:780–782.

    Article  PubMed  Google Scholar 

  35. AIDS Info: Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. Available at http://AIDSinfo.nih.gov. Accessed April 2009.

  36. Fernandes GC, Vieira MA, Lourenco MC, et al.: Inflammatory paradoxical reaction occurring in tuberculosis patients treated with HAART and rifampicin. Rev Inst Med Trop Sao Paulo 2002, 44:113–114.

    PubMed  Google Scholar 

  37. Bekker LG, Haslett P, Maartens G, et al.: Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis. J Infect Dis 2000, 181:954–965.

    Article  PubMed  CAS  Google Scholar 

  38. Schoeman JF, Springer P, van Rensburg AJ, et al.: Adjunctive thalidomide therapy for childhood tuberculous meningitis: results of a randomized study. J Child Neurol 2004, 19:250–257.

    Article  PubMed  Google Scholar 

  39. Schoeman JF, Fieggen G, Seller N, et al.: Intractable intracranial tuberculous infection responsive to thalidomide: report of four cases. J Child Neurol 2006, 21:301–308.

    Article  PubMed  Google Scholar 

  40. Roberts MT, Mendelson M, Meyer P, et al.: The use of thalidomide in the treatment of intracranial tuberculomas in adults: two case reports. J Infect 2003, 47:251–255.

    Article  PubMed  CAS  Google Scholar 

  41. John M, French MA: Exacerbation of the inflammatory response to Mycobacterium tuberculosis after antiretroviral therapy. Med J Aust 1998, 169:473–474.

    PubMed  CAS  Google Scholar 

  42. Bell HC, Heath CH, French MA: Pulmonary Mycobacterium celatum immune restoration disease: immunopathology and response to corticosteroid therapy. AIDS 2005, 19:2047–2049.

    Article  PubMed  Google Scholar 

  43. Wallis RS, Johnson JL, Okwera A, et al.: Pentoxifylline in human immunodeficiency virus-positive tuberculosis: safety at 4 years. J Infect Dis 1998, 178:1861.

    Article  PubMed  CAS  Google Scholar 

  44. Boelaert JR, Goddeeris KH, Vanopdenbosch LJ, Casselman JW: Relapsing meningitis caused by persistent cryptococcal antigens and immune reconstitution after the initiation of highly active antiretroviral therapy. AIDS 2004, 18:1223–1224.

    Article  PubMed  Google Scholar 

  45. Lipman MC, Carding SK: Successful drug treatment of immune reconstitution disease with the leukotriene receptor antagonist, montelukast: a clue to pathogenesis? AIDS 2007, 21:383–384.

    Article  PubMed  Google Scholar 

  46. Peters-Golden M, Canetti C, Mancuso P, Coffey MJ: Leukotrienes: underappreciated mediators of innate immune responses. J Immunol 2005, 174:589–594.

    PubMed  CAS  Google Scholar 

  47. Jarvis B, Markham A: Montelukast: a review of its therapeutic potential in persistent asthma. Drugs 2000, 59:891–928.

    Article  PubMed  CAS  Google Scholar 

  48. Blackmore TK, Manning L, Taylor WJ, Wallis RS: Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Clin Infect Dis 2008, 47:e83–e85.

    Article  PubMed  CAS  Google Scholar 

  49. Pires A, Nelson M, Pozniak AL, et al.: Mycobacterial immune reconstitution inflammatory syndrome in HIV-1 infection after antiretroviral therapy is associated with deregulated specific T-cell responses: beneficial effect of IL-2 and GM-CSF immunotherapy. J Immune Based Ther Vaccines 2005, 3:7.

    Article  PubMed  CAS  Google Scholar 

  50. Michailidis C, Pozniak AL, Mandalia S, et al.: Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. Antivir Ther 2005, 10:417–422.

    PubMed  Google Scholar 

  51. El-Bradey MH, Cheng L, Song MK, et al.: Long-term results of treatment of macular complications in eyes with immune recovery uveitis using a graded treatment approach. Retina 2004, 24:376–382.

    Article  PubMed  Google Scholar 

  52. Bicanic T, Brouwer AE, Meintjes G, et al.: Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS 2009, 23:701–706.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Graeme Meintjes.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marais, S., Wilkinson, R.J., Pepper, D.J. et al. Management of patients with the immune reconstitution inflammatory syndrome. Curr HIV/AIDS Rep 6, 162–171 (2009). https://doi.org/10.1007/s11904-009-0022-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11904-009-0022-z

Keywords

Navigation